Gerresheimer AG (ETR:GXI)
Germany · Delayed Price · Currency is EUR | Market Cap | 1.08B +22.3% |
| Revenue (ttm) | 2.32B +15.6% |
| Net Income | -405.82M |
| EPS | -11.75 |
| Shares Out | 34.54M |
| PE Ratio | n/a |
| Forward PE | 14.87 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 15,249 |
| Open | 30.96 |
| Previous Close | 31.20 |
| Day's Range | 30.74 - 31.36 |
| 52-Week Range | 14.83 - 34.20 |
| Beta | 0.47 |
| Analysts | Hold |
| Price Target | 27.54 (-11.62%) |
| Earnings Date | Oct 30, 2026 |
About Gerresheimer AG
Gerresheimer AG, together with its subsidiaries, provides drug containment solutions in Germany and internationally. The company operates through three divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. It offers prefillable syringes, plastic and glass packaging solutions, vials, glass cartridges and ampoules, bottles and containers, and containers, bottles, caps, closures, applicators, and accessories; development, industrialization, and contract manufacturing of drug delivery programs; project and quality manag... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for GXI stock is "Hold." The 12-month stock price target is €27.54, which is a decrease of -11.62% from the latest price.
News
Gerresheimer AG - Depositary Receipt Price Target Decreased by 65.24% to $8.20
The average one-year price target for Gerresheimer AG - Depositary Receipt (OTCPK:GRRMY) has been revised to $8.20 / share. This is a decrease of 65.24% from the prior estimate of $23.59 dated Februar...
Gerresheimer Q3 Earnings Call Highlights
Gerresheimer ETR: GXI reported preliminary third-quarter 2026 revenue growth across all three business segments, while adjusted EBITDA was broadly stable as inventory reductions weighed on profitabili...
Gerresheimer AG Earnings Call Transcript: Q3 2026
Q3 revenue grew across all segments, while inventory discipline weighed on adjusted EBITDA and cash flow. FY26 guidance remains intact; divestitures are set to accelerate debt reduction and leverage improvement.
Gerresheimer AG Earnings release: Q3 2026
Gerresheimer AG released its Q3 2026 earnings on October 30, 2026, summarizing the period's financial results.
Gerresheimer AG Slides: Q3 2026
Gerresheimer AG has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 30, 2026.
Gerresheimer Posts Q3 2026 Revenue Growth, Stable Adjusted EBITDA
Drug-delivery demand powered Gerresheimer’s Q3 revenue growth, but earnings pressure persisted as the company prepared for a stronger Q4, refinancing and the PPP sale.
What Gerresheimer (GXI) Said on Its Q2 Earnings Call
Gerresheimer ETR: GXI reported a sequential improvement in preliminary second-quarter 2026 results, with adjusted EBITDA rising more than 50% from the first quarter as operational initiatives began to...
Gerresheimer AG Earnings Call Transcript: Q2 2026
Q2 2026 saw a strong operational recovery, with adjusted EBITDA up over 50% sequentially and all segments contributing to growth. Major divestitures are on track to reduce leverage, while transformation initiatives target significant EBITDA improvement by 2028. Transformation and cost efficiencies are progressing, with a leaner, more focused business model emerging.
Gerresheimer AG Slides: Q2 2026
Gerresheimer AG has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on September 30, 2026.
Gerresheimer AG Earnings release: Q2 2026
Gerresheimer AG released its Q2 2026 earnings on September 30, 2026, summarizing the period's financial results.
Gerresheimer reports lower half-year core profit
Drug-packaging maker Gerresheimer reported a lower core profit for the first half of 2026 on Wednesday, as weakness in its Moulded Glass business and lower demand for injection vials weighed o...
Gerresheimer AG Slides: FY 2026
Gerresheimer AG has posted slides in relation to its FY 2026 quarterly earnings report, which was published on September 1, 2026.
Gerresheimer Q1 Earnings Call Highlights
Gerresheimer ETR: GXI reported preliminary first-quarter 2026 results that showed modest revenue growth but lower earnings as the packaging and drug-delivery company prioritized cash preservation, red...
Gerresheimer AG Earnings Call Transcript: Q1 2026
Q1 2026 saw a strong focus on cash flow, with CapEx halved and inventory tightly managed, resulting in improved free cash flow despite lower EBITDA. Portfolio transformation is advancing with the sale of Centor and PPP, targeting leverage below 3x and operational improvements of EUR 50–70 million EBITDA by 2028.
Gerresheimer AG Slides: Q1 2026
Gerresheimer AG has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on August 27, 2026.
Gerresheimer AG Earnings release: Q1 2026
Gerresheimer AG released its Q1 2026 earnings on August 27, 2026, summarizing the period's financial results.
Gerresheimer price target raised to EUR 26 from EUR 22 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Gerresheimer (GRRMF) to EUR 26 from EUR 22 and keeps a Hold rating on the shares.
Gerresheimer upgraded to Neutral from Sell at UBS
UBS upgraded Gerresheimer (GRRMF) to Neutral from Sell with a price target of EUR 28.50, up from EUR 12.90. The firm sees a more balanced risk/reward profile following the sale…
Gerresheimer upgraded to Hold from Sell at DZ Bank
DZ Bank upgraded Gerresheimer (GRRMF) to Hold from Sell with a EUR 30 price target
Germany's Gerresheimer to sell two units to Apax for $1.71 billion including debt
German drugs packaging firm Gerresheimer said on Wednesday it was selling two of its packaging units to private equity group Apax Funds for €1.5 billion ($1.71 billion) including debt.
Gerresheimer upgraded to Market Perform from Underperform at Bernstein
Bernstein analyst Delphine Le Louet upgraded Gerresheimer (GRRMF) to Market Perform from Underperform with a EUR 28.70 price target The firm cites valuation for the upgrade.
Gerresheimer Q4 Earnings Call Highlights
Gerresheimer ETR: GXI said it has completed a broad review of compliance and accounting matters, published its audited 2025 annual report and is now focused on selling Centor, refinancing debt and imp...
Gerresheimer AG Earnings Call Transcript: Q4 2025
Restated and audited 2025 financials reflect extensive compliance work, with revenue at EUR 2.3 billion and flat organic growth. Margin improvement and cash generation are key 2026 priorities, supported by the GTO transformation and planned Centor sale and refinancing.
Gerresheimer AG Annual report: Q4 2025
Gerresheimer AG has published its Q4 2025 annual report on June 29, 2026.
Gerresheimer AG Annual report: Q4 2025
Gerresheimer AG has published its Q4 2025 annual report on June 29, 2026.